Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Islam Elkonaissi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Oncology Reviews|March 22, 2021
Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncologyHasan Kobat, Islam Elkonaissi, Mehmet Tevfik Dorak, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 21, 2023
Multiple cardiotoxicities during osimertinib therapyHasan Kobat, Michael Davidson, Islam Elkonaissi, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2022
Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Hasan Kobat, Islam Elkonaissi, Emma Foreman, et al.
Clinical Lung Cancer|October 25, 2023
Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World StudyHasan Kobat, Islam Elkonaissi, Emma Foreman, et al.
International Immunopharmacology|May 24, 2024
CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow upMohamed Elmarasi, Islam Elkonaissi, Ahmed Adel Elsabagh, et al.
Cancers|January 11, 2025
Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaMaria Benkhadra, Rola Ghasoub, Reem Hajeomar, et al.
Journal of Health Economics and Outcomes Research|July 22, 2024
Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf CountriesAnas Hamad, Shereen Al-Azzazy, Ruba Y Taha, et al.
Cancers|June 19, 2024
Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert OpinionGiuseppe Saglio, Mohamed Yassin, Ahmad Alhuraiji, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Oncology Reviews|March 22, 2021
Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncologyHasan Kobat, Islam Elkonaissi, Mehmet Tevfik Dorak, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 21, 2023
Multiple cardiotoxicities during osimertinib therapyHasan Kobat, Michael Davidson, Islam Elkonaissi, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 15, 2022
Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Hasan Kobat, Islam Elkonaissi, Emma Foreman, et al.
Clinical Lung Cancer|October 25, 2023
Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World StudyHasan Kobat, Islam Elkonaissi, Emma Foreman, et al.
International Immunopharmacology|May 24, 2024
CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow upMohamed Elmarasi, Islam Elkonaissi, Ahmed Adel Elsabagh, et al.
Cancers|January 11, 2025
Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaMaria Benkhadra, Rola Ghasoub, Reem Hajeomar, et al.
Journal of Health Economics and Outcomes Research|July 22, 2024
Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf CountriesAnas Hamad, Shereen Al-Azzazy, Ruba Y Taha, et al.
Cancers|June 19, 2024
Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert OpinionGiuseppe Saglio, Mohamed Yassin, Ahmad Alhuraiji, et al.
Pageof 1